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1 Drug description 
Generic/Brand name/ATC code:  
Enzalutamide/Xtandi®/L02BB03 
Developer/Company:  
Medivation, Inc. and Astellas Pharma US, Inc. 
Description:  
Enzalutamide (or MDV3100) targets multiple steps in the androgen-receptor-
signaling pathway, the major driver of prostate-cancer growth [1, 2]. Through 
a mechanism that is reported to be different from other approved androgen-
receptor (AR) antagonists, enzalutamide inhibits the activity of prostate 
cancer cell ARs, which may result in a reduction of prostate cancer cell pro-
liferation and correspondingly, in a reduction of the serum prostate specific 
antigen (PSA) level. AR over-expression in prostate cancer represents a key 
mechanism associated with prostate cancer hormone resistance [3, 4]. 
Capsules containing 40 mg are available. The recommended dose and sched-
ule for enzalutamide is 160 mg orally once daily until disease progression 
or unacceptable toxicity [5]. 
 
 
2 Indication 
Enzalutamide (Xtandi®) is indicated for the treatment of patients with met-
astatic castration-resistant prostate cancer (CRPC) who have previously re-
ceived docetaxel. 
 
 
3 Current regulatory status 
On April 25, 2013, EMA’s Committee for Medicinal Products for Human 
Use adopted a positive opinion, recommending the granting of a marketing 
authorisation for the medicinal product Xtandi®, 40 mg, intended for the 
treatment of adult men with metastatic CRPC whose disease has progressed 
on or after docetaxel therapy [6]. 
In the US, the U. S. Food and Drug Administration approved enzalutamide 
for the treatment of patients with metastatic CRPC who have previously re-
ceived docetaxel on August 31, 2012 [7]. 
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4 Burden of disease 
In 2010 about 4,500 men were newly diagnosed with prostate cancer in Aus-
tria and 1,125 died. Prostate cancer is therefore the most common type of 
cancer in Austrian men. Due to widespread prostate-specific antigen (PSA) 
testing, prostate cancer is mostly diagnosed at an early, asymptomatic stage 
of disease, resulting in 60% of patients which are diagnosed before the tu-
mour has spread [8]. From 2005-2009, the median age at diagnosis for cancer 
of the prostate was 67 years [9]. 
Risk factors for developing prostate cancer include age, ethnicity, family his-
tory, diet and genetic factors such as mutations in BRCA1 and BRCA2 genes. 
Prognostic Factors are age, extent of tumour, histologic grade of tumour and 
the PSA level [10]. 
Staging is done by using the TNM system which provides information for 
choosing the initial therapy. Other factors which impact on the choice of ini-
tial therapy are life expectancy, comorbidities, therapeutic side-effects and 
patients’ preferences. Besides the TNM system, the Gleason score is used in 
addition to establish prognosis. This score is a histopathologic grading sys-
tem which distinguishes well and poorly differentiated prostate tissue [11]. 
Prognosis strongly depends on the stage at diagnosis. If the tumour is con-
fined to the prostate gland, a median survival of more than 5 years can be ex-
pected. For locally advanced forms of prostate cancer, cure is rarely possible, 
but median survival is still about 5 years. Patients with metastasised tumours 
have a median survival of 1-3 years [2, 12]. 
 
 
5 Current treatment 
Androgen deprivation therapy (ADT) is generally the initial treatment for 
men with metastatic prostate cancer. Despite initial response rates of 80 to 
90%, nearly all men eventually develop progressive disease following ADT. 
Disease progression can either be defined as a rise in serum levels of PSA, as 
progression of pre-existing disease and/or as the development of new metas-
tases [10]. 
If PSA level rises despite castrate levels of testosterone (serum testosterone 
<20 ng/dL) the cancer is called “castrate-resistant”, “hormone-refractory” or 
“androgen-independent”. Therapeutic options for CRPC: 
 Multiple and sequential secondary hormone therapies including with-
drawal of ADT, antiandrogen therapy, cytochrome P450 inhibitors, 
oestrogens and corticosteroids [10]. 
 Immunotherapy with sipuleucel-T indicated for minimally sympto-
matic/asymptomatic and chemotherapy-naive patients [4, 12, 13]. 
 Docetaxel injection concentrate in combination with prednisone [2, 14]. 
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After disease progression on first-line docetaxel, other therapy options besides 
enzalutamide are:  
 Abiraterone acetate: a CYP17 inhibitor usually administered with 
prednisone [15-17]  
 Cabazitaxel: a ‘second generation’ taxane in addition to prednisone 
[13, 18] 
 Radium-223 chloride: a calcium-mimetic radiopharmaceutical with 
high bone affinity [14, 19, 20]. 
 
 
6 Evidence 
A literature search was conducted on the 4th of April 2013 in 4 databases (Med-
line, Embase, CRD, Cochrane Central). Search terms were “prostate cancer”, 
“enzalutamide”, “MDV 3100”and “xtandi”. Overall, 139 references were iden-
tified. Eligible for inclusion were phase III trials (full text, abstracts) and 
phase II studies published as full text but also other study designs such as 
results from compassionate-use programmes or meta-analyses. After apply-
ing these inclusion criteria, one phase III trial [21] and one phase II trial [22] 
were included in this report. 
 
 
6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Increased survival with enzalutamide in prostate cancer after chemotherapy [21] 
Study  
identifier 
NCT00974311, AFFIRM trail 
Design double-blind, placebo-controlled trial, phase III, randomization in a 2:1 ratio, 
international, multi-centre (156 sites in 15 countries) 
Duration  Enrolment: September 2009 – November 2010 
Median follow-up: 14.4 months 
Cut-off date for analysis: 25. September 2011 
Hypothesis Superiority 
90% to detect a hazard ratio of 0.76 for death in the enzalutamide group, compared 
with the placebo group, with a two sided type I error rate of 0.05. 
Funding Medivation and Astellas Pharma Global Development 
Treatment 
groups 
Intervention 
(n=800) 
enzalutamide (160 mg orally once daily as four 40-mg capsules), 
until unacceptable toxicity, disease progression as defined in the 
protocol, death, or withdrawal. 
Control 
(n=399) 
matched placebo capsules, until unacceptable toxicity, disease 
progression as defined in the protocol, death, or withdrawal. 
Endpoints 
and 
definitions 
Overall survival 
(primary outcome) 
OS time from randomization to death from any cause 
PSA response PSA-
RESP 
reduction in the PSA level from baseline by 50% or 
more or 90% or more, as confirmed on an additional 
PSA evaluation performed 3 or more weeks later 
options after first-line 
docetaxel therapy ... 
literature search in  
4 databases: 139 hits 
included: 1 phase III,  
1 phase II 
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Endpoints 
and 
definitions 
Soft-tissue 
response 
- defined by the Response Evaluation Criteria in Solid 
Tumours (RECIST), version 1.1 
Radiographic 
progression  
free-survival 
R-PFS time from randomization to the earliest objective 
evidence of radiographic progression or death due to 
any cause 
Time to first 
skeletal-related 
event 
- time from randomization to the occurrence of the first 
skeletal-related event. A skeletal-related event was defined 
as radiation therapy or surgery to bone, pathologic 
bone fracture, spinal cord compression, or change of 
antineoplastic therapy to treat bone pain 
Time to PSA 
progression 
TTPSA defined as an increase by a factor of 1.25 over the baseline 
level (for patients in whom the PSA level had not 
decreased) or over the nadir level (for patients in whom 
the PSA level had decreased) and an increase in the 
absolute PSA level by at least 2 ng per milliliter, which 
was confirmed by a repeat measurement 
Quality of life, 
FACT-P 
QOL, 
FACT-P 
defined as a 10-point improvement in their global FACT-P 
score, as compared with baseline, on two consecutive 
measurements obtained at least three weeks apart. 
FACT-P is a multidimensional, self-reported, quality of 
life instrument used with prostate cancer patients, 
consisting of 27 core items to assess patient function in 
four domains: physical, social/family, emotional, and 
functional wellbeing; and is supplemented by 12 specific 
items to assess for prostate-related symptoms.  
Results and analysis 
Analysis  
description 
ITT 
A single interim analysis was planned after 520 deaths (80% of the 650 total events).  
In the primary analysis, a log-rank test to evaluate overall survival, with stratification 
according to the ECOG performance-status score was used. 
Other endpoints were tested by means of the stratified log-rank test in a protected 
hierarchical manner, each at the two-sided significance level of 0.05 
Analysis  
population 
Inclusion  histologically or cytologically confirmed adenocarcinoma of the 
prostate without neuroendocrine differentiation or small cell 
features; ongoing androgen deprivation therapy with a gonadotropin 
releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or 
medical castration); serum testosterone level <1.7 nmol/L (50 ng/dL); 
progressive disease by PSA or imaging after docetaxel-based chemo-
therapy in the setting of medical or surgical castration; disease 
progression defined as one or more of the following three criteria: 
1. PSA progression by a minimum of three rising PSA levels with an 
interval of ≥1 week between each determination.  
PSA value ≥2 μg/L (2 ng/ml) 
2. Soft tissue disease progression defined by RECIST 
3. Bone disease progression defined by two or more new lesions 
on bone scan 
 No more than two prior chemotherapy regimens with at least one 
regimen containing docetaxel 
 ECOG performance status 0–2 
Exclusion  metastases in the brain or active epidural disease  
 treatment with androgen receptor antagonists (bicalutamide, 
flutamide, nilutamide), 5-α reductase inhibitors (finasteride, 
dutasteride), estrogens, or chemotherapy within four weeks of 
enrolment  
 treatment with therapeutic immunizations for prostate cancer  
(e.g., PROVENGE®) 
 history of prostate cancer progression on ketoconazole  
 clinically significant cardiovascular disease 
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Analysis  
population 
Characteristics age – median (range) (%): I 69 (41–92) vs C 69 (49–89) 
≥75 years (number of patients (%)): I 199 (24.9) vs C 104 (26.1) 
years since diagnosis: I 5.9 vs C 6.0 
ECOG – 0 or 1/2 (%): I 91.3/8.8 vs C 92.0/80 
prior chemotherapy regimens 1/2/≥3 (%): I 72.4/24.5/3.1 vs C 74.2/23.8/2.0 
baseline PSA (median (range)): I 107.7 (0.2–11794.1) vs C 128.3  
(0.0–19000.0) 
PSA progression at baseline (%): yes/no : I 88.8/11.3 vs C 89.5/10.5 
Descriptive 
statistics 
and 
estimated 
variability 
*P – value 
<0.001 
Treatment group Control Intervention 
number of subjects, overall N= 399 N= 800 
median OS, months 
95%CI  
13.6 
11.3–15.8  
18.4 
17.3–NR 
confirmed PSA decline: 
≥1 postbaseline PSA assessment no. (%) 
PSA response, no. of patients/total no. (%): 
decline ≥50% from baseline * 
decline ≥90% from baseline * 
 
330 (83) 
 
5/330 (2) 
3/330 (1) 
 
731 (91) 
 
395/731 (54) 
181/731 (25) 
soft-tissue objective response: 
patient with measurable disease no. (%) 
CR + PR, no. /total no. (%) * 
 
208 (52) 
8/208 (4) 
 
446 (56) 
129/446 (29) 
QOL response, FACT-P: 
patients with ≥1 postbaseline assessment no. (%) 
QOL response no/total no. (%) * 
 
257 (64) 
47/257 (18) 
 
651 (81) 
281/651 (43) 
median time to PSA progression, months 
95%CI 
3.0 
2.9–3.7 
8.3 
5.8–8.3 
median R-PFS, months 
95%CI 
2.9 
2.8–3.4 
8.3 
8.2–9.4 
median time to first skeletal-related event, 
months 
95%CI 
 
13.3 
9.9–NR 
 
16.7 
14.6–19.1 
Effect 
estimate 
per 
comparison 
 
Comparison groups 
 Intervention  
vs Control 
OS HR 0.63 
95% CI 0.53–0.75 
P value  <0.001 
PSA progression HR 0.25 
95% CI 0.20–0.30 
P value  <0.001 
R-PFS HR 0.40 
95% CI 0.35–0.47 
P value  <0.001 
time to first skeletal-related event HR 0.69 
95% CI 0.57–0.84 
P value  <0.001 
Abbreviations: C = control, CI = confidence interval, CR = complete response, ECOG = Eastern Cooperative Oncology Group, 
FACT-P = Functional Assessment of Cancer Therapy-Prostate, HR = hazard ratio, I =intervention, no = number, OS = over-
all survival, PFS = progression free survival, PR = partial response, PSA-RESP = PSA response, R-PFS = radiographic 
progression free survival, TSP = time to symptom progression, TTPSA = time to PSA progression, NR = not reached 
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Table 2: Adverse Events 
Outcome, n (%) I (n=800) C (n= 399) 
Grade (according to CTC version 3.0) Any Grade Grade ≥3 Any Grade Grade ≥3 
≥1 adverse event  785 (98) 362 (45) 390(98) 212 (53) 
Any serious adverse event 268 (34) 227 (28) 154 (39) 134 (34) 
Discontinuation owing to adverse event 61 (8) 37 (5) 39 (10) 28 (7) 
Adverse event leading to death 23 (3) 23 (3) 14 (4) 14 (4) 
Fatigue 269 (34) 50 (6) 116 (29) 29 (7) 
Diarrhoea 171 (21) 9 (1) 70 (18) 1 (<1) 
Hot Flash 162 (20) 0 41 (10) 0 
Musculoskeletal pain 109 (14) 8 (1) 40 (10) 1 (<1) 
Headache 93 (12) 6(<1) 22 (6) 0 
Any cardiac disorder 49 (6) 7 (1) 30 (8) 8 (2) 
Myocardinal infarction 2 (<1) 2(<1) 2 (<1) 2 (<1) 
Abnormality on liver-function testing 8 (1) 3 (<1) 6 (2) 3 (<1) 
Seizure 5 (<1) 5 (<1) 0 0 
N = number of patients 
 
The AFFIRM trial, a phase III study included 1,199 men with metastatic 
CRPC after previous docetaxel chemotherapy. 72.4% of the patients treated 
with enzalutamide and 74.2% of the placebo group had one prior chemother-
apy regimen, about 24% in both groups had received two cytotoxic chemo-
therapy regimens and 25 patients (3.1%) of the intervention group and 8 pa-
tients (2.0%) getting placebo had been treated with ≥3 prior chemotherapeu-
tic regimens. ECOG performance status was 0 or 1 in 91.3% in the interven-
tion group and 92.0% in the control group. 199 patients (24.9%) in the inter-
vention group and 104 patients (26.1%) getting placebo were ≥75 years old. 
Patients were randomly assigned to either the intervention group receiving 
enzalutamide at a dose of 160 mg per day (800 patients) orally or to the pla-
cebo group (399 patients). The primary endpoint was overall survival (OS). 
The study was stopped after a planned interim analysis at the time of 520 
deaths. Placebo groups’ patients were offered treatment with enzalutamide. 
For all patients receiving enzalutamide the median overall survival was 18.4 
months (95% CI, 17.3 to not yet reached) and 13.6 months (95% CI, 11.3 to 
15.8) among all patients receiving placebo. Patients aged ≥65 years showed a 
median overall survival of 18.4 (intervention group) and 13.9 (control group). 
308 of 800 patients (39%) died in the enzalutamide group and 212 of 399 pa-
tients (53%) died in the placebo group. The interim analysis indicated, that 
the use of enzalutamide resulted in a 37% relative reduction in the risk of 
death compared with placebo (hazard ratio HR for death, 0.63, 95% CI, 0.53 
to 0.75, P<0.001).  
Also other outcomes such as PSA-level response rate (54% vs. 2%, P<0.001) 
and soft-tissue response rate (29% vs. 4%, P<0.001) showed improved results 
for patients treated with enzalutamide. Of note, separate results for complete 
and partial responses of the soft-tissue response were not stated. However, the 
time to PSA progression (8.3 vs. 3.0 months, HR 0.25, P<0.001), radiographic 
progression-free survival (8.3 vs. 2.9 months, HR 0.40, P<0.001) and the time 
to the first skeletal-related event (16.7 vs. 13.3 months, HR 0.69, P<0.001) 
AFFIRM trial enrolled 
1,199 men treated with 
enzalutamide or placebo 
 
primary endpoint was 
overall survival 
overall survival 
improved in the 
enzalutamide group 
improved secondary 
outcomes in the 
intervention group 
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were also statistically improved in the intervention group. Quality of life as-
sessed by the FACT-P scale was improved with enzalutamide (43% vs. 18%, 
P<0.001). 
Adverse events (AEs) of any grade were very common in both groups (98%), 
with fatigue, diarrhoea and hot flashes being the most frequent ones in the 
enzalutamide group. AEs of ≥grade 3 were with 45.3% in the enzalutamide 
group less frequent than in the placebo group (53.1%). The median time to 
the first adverse event was 12.6 months in the enzalutamide group compared 
to 4.2 months in the placebo group. Cardiac disorders were noted in 6% of 
patients receiving enzalutamide and in 8% of patients receiving placebo (with 
cardiac disorders of ≥grade 3 in 1% and 2%). Seizures were reported in 5 of 
800 patients (0.6%) receiving enzalutamide, several of whom had predispos-
ing conditions or concomitant treatments. Discontinuation due to AEs of any 
grade was recorded in the enzalutamide group in 61 patients (8%) and due 
to AEs ≥grade 3 in 37 patients (5%). In the placebo group 39 patients (10%) 
stopped participation because of any grade AE and 28 patients (7%) because 
of AEs grade ≥3. AEs leading to death occurred in 23 patients (3%) of the 
enzalutamide group and in 14 patients (4%) of the control group. 
 
 
6.2 Efficacy and safety – further studies 
A phase 1–2 study [22] investigated the safety and tolerability of enzalutam-
ide in patients with metastatic CRPC both previously treated with chemo-
therapy and chemotherapy-naive. 46% had not received any prior chemother-
apy, whereas 54% had been treated with a chemotherapeutic agent. Further-
more the maximum tolerated dose should be defined. 140 patients were given 
an oral daily dose of either 30 mg (n=3), 60 mg (n=27), 150 mg (n=28), 240 mg 
(n=29), 360 mg (n=28), 480 mg (n=22) and 600 mg (n=3) enzalutamide dai-
ly. Antitumour effects were shown at all doses: PSA decreased of 50% occured 
in 78 (56%) patients, partial responses in soft tissue were shown in 13 (22%) 
of 59 patients. Of these, 4 patients (12%) had received previous chemotherapy 
and 9 (36%) were chemotherapy-naive. Stabilised bone disease was observed 
in 61 (56%) of 109 patients. The median time to progression was 47 weeks 
(95% CI 34 – not reached) for disease progression. The maximum tolerated 
dose for the treatment (>28 days) was 240 mg. The most common adverse 
event (grade 3-4) was fatigue, which generally developed after the 30-day safe-
ty assessment. 16 patients (11%) reported dose-dependent fatigue. Anorexia 
and nausea were also related to treatment. At doses of 240 mg and above an 
increasing proportion of patients needed dose reductions because of AEs but 
none of the 58 patients given doses of 30 mg, 60 mg and 150 mg per day. 
 
 
7 Estimated costs 
No cost estimates are available for Austria. The costs for one month’s treat-
ment with Xtandi® in the US are estimated at $7,450 that is an average of 
$59,600/patient (assuming a median of eight cycles is administered) [23]. 
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8 Ongoing research 
At http://clinicaltrials.gov/ one phase III study for the investigated indication 
was found: 
 NCT01606982: multicenter, single-arm, open label study aiming to 
provide expanded access to enzalutamide and monitor its safety in pa-
tients with progressive CRPC previously treated with docetaxel-based 
chemotherapy. An estimated study completion date is not available. 
Another ongoing phase III study investigates use of enzalutamide at an earlier 
phase (chemotherapy naive patients): 
 NCT01212991: (PREVAIL): multinational, randomized, double-blind, 
placebo-controlled efficacy and safety study of enzalutamide in chemo-
therapy-naive patients with progressive metastatic prostate cancer who 
have failed ADT. The purpose of this study is to determine the benefit 
of enzalutamide versus placebo as assessed by overall survival and pro-
gression-free survival in patients with progressive metastatic prostate 
cancer who have failed androgen deprivation therapy but not yet re-
ceived chemotherapy. Estimated study completion date: September 2014. 
Several other phase II and III studies are currently conducted in different 
stages of prostate cancer as not yet hormone treated, localized prostate can-
cer and CRPC (NCT01193244) or in combination with other drug inter-
ventions like abiraterone acetate, cabozantinib, galeterone (NCT00676650, 
NCT01688492). Enzalutamide is also being assessed for incurable breast can-
cer (NCT01597193).  
 
 
9 Commentary 
Enzalutamide is currently under evaluation by the Committee for Medicinal 
Products for Human Use and was approved by the FDA in August 2012 for 
the treatment of patients with metastatic CRPC who were previously treated 
with docetaxel. 
A phase III randomized study, the AFFIRM trial, compared enzalutamide 
with placebo in men with progressive CRPC after docetaxel chemotherapy. 
24% had received two prior cytotoxic chemotherapy regimens. For patients 
treated with enzalutamide overall survival was extended by 4.8 months (18.4 
vs. 13.6 months, HR, 0.63, P <0.001). All secondary endpoints including pro-
portion of patients with PSA decline, soft-tissue response, quality-of-life re-
sponse (FACT-P scale), time to PSA progression, radiographic progression 
free survival and the time to the first radiographic skeletal event favoured 
patients treated with enzalutamide. 
AEs of any grade were very common in both groups (98%), with fatigue, di-
arrhoea and hot flashes being the most frequent ones in patients treated with 
enzalutamide. Higher grade AEs (i.e. ≥3) were less frequent in the enzalu-
tamide group than in the placebo group, as were any serious AE of grade ≥3. 
Consequently, fewer patients discontinued therapy with enzalutamide than 
with placebo. Seizures were reported in 5 (0.6%) of the patients treated with 
one ongoing  
phase III trial 
one trial with 
enzalutamide in 
chemotherapy-naive 
patients 
several current studies 
in different disease 
stages and indications 
approved by  
FDA in 2012 
enzalutamide compared 
with placebo in men 
with progressive CRPC 
after prior 
chemotherapy 
most common adverse 
event: fatigue, 
diarrhoea and hot 
flashes  
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enzalutamide, but even though the use of enzalutamide is not contraindicat-
ed in patients with history of seizures, the AFFIRM and the PREVAIL trial 
had excluded patients known at risk for seizure. The FDA has therefore re-
quired an open-label safety study in high-risk seizure patents to elicit the 
risk of seizures (study results will be available in 2019) [24-26]. 
Until recently, therapeutic options for patients with CRPC progressing on 
docetaxel therapy were limited. Now, enzalutamide represents the third phar-
maceutical agent to significantly increase survival in men with CRPC fol-
lowing docetaxel. However, gains in OS were established for enzalutamide in 
comparison to placebo which cannot be considered a relevant comparator 
anymore. Also the authors’ of the phase III trial acknowledged that fact but 
highlighted that at study initiation no treatment option for these patients 
existed. Since other drugs such as cabazitaxel and abiraterone acetate are li-
censed for CRPC patients who have received docetaxel previously, studies 
comparing these agents directly are of interest. Even though the HRs are 
similar for all these 3 agents, absolute gains in OS differ (enzalutamide 4.8 
months, abiraterione acetate 3.9 months, cabazitaxel 2.4 months)[16, 18, 21] 
but since cross-study comparisons are dangerous these results have to be in-
terpreted with caution. However, until direct comparisons between these dif-
ferent agents have become available, other criteria have to be applied to select 
the most appropriate therapy. For example, enzalutamide is the first agent 
for which data on quality of life were available at market authorisation.  
Further, different modes of administration may determine patients’ prefer-
ences since cabazitaxel is administered intravenously every 3 weeks, whereas 
enzalutamide and abiraterone acetate are taken orally, a route of administra-
tion patients may prefer [16, 18]. In addition, co-morbidities, concomitant 
therapies and especially the toxicity profiles of these drugs have to be taken 
into account when choosing the most appropriate regimen for previously 
treated patients with metastatic CRPC.  
Currently, enzalutamide is only approved in the US for those who have al-
ready received docetaxel, but since the PREVAIL trial (NCT01212991) is 
investigating this drug for earlier lines of therapy it is likely that future in-
dications will comprise docetaxel-naive patients too. Additionally, several trials 
are under way investigating enzalutamide in combination with other agents, 
for example enzalutamide in combination with docetaxel (NCT01565928) or 
abiraterone (NCT01650194). With $7,450/month, enzalutamide will cost on 
average $59,600/patient in the US (assuming a median of eight cycles is ad-
ministered). Cost estimates for Austria are not yet available, but it can be as-
sumed that the costs will be comparable to those of other drugs licensed for 
this indication, e.g. abiraterone acetate costs about 3,450 € (as reimbursed by 
health insurance) per month [27, 28]. These costs will rise when enzalutam-
ide will be given in combination with other agents used for prostate cancer 
but also if enzalutamide moves into the pre-chemotherapy setting, as a greater 
number of cycles may be administered [25, 29].  
Recent therapeutic advances for managing advanced prostate cancer offer new 
treatment options including enzalutamide for patients with CRPC. Multiple 
challenging questions as how to best combine, optimally sequence and select 
agents for treatment (like abiraterone acetate, cabazitaxel, enzalutamide) are 
therefore emerging and should be addressed in further clinical trials [30, 31]. 
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